RxDoctor Payments Data

Yanique Donaldson

Nurse Practitioner · Marietta, GANPI 1689374290

Payments from drug & device makers

$3,181in general payments, 2019–2025

Across 115 payments — averaging $27.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$810
  • Sanofi-aventis U.S. LLC$391
  • Lilly USA, LLC$366
  • Dexcom, Inc.$271
  • AstraZeneca$266
  • GSK$212
  • plus $865 from 14 others

What the payments were for

  • Food & beverage$3,181100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,181 in reported general payments places this provider in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$43,130
Medicare patients
363
Services billed
510

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide30$34,230
EliquisApixaban40$27,251
WegovySemaglutide20$26,515
FarxigaDapagliflozin Propanediol13$21,386
MounjaroTirzepatide21$21,020
JanuviaSitagliptin Phosphate24$16,425
XareltoRivaroxaban16$8,993
Atorvastatin Calcium164$1,782
SynthroidLevothyroxine Sodium13$1,632
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,349
Levothyroxine Sodium123$1,148
Olmesartan Medoxomil30$1,104
Metformin Hcl ErMetformin Hcl53$892
Rosuvastatin Calcium70$823
Venlafaxine Hcl ErVenlafaxine Hcl24$775

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$810$60,74450 claims
Lilly USA, LLCMounjaro, Olanzapine$366$21,39934 claims
AstraZenecaFarxiga$266$21,38613 claims
AbbVieSynthroid$69$1,63213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →